Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
25,669,673
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
24,065,900
-
Shares change
-
+115,674
-
Total reported value, excl. options
-
$384,816,806
-
Value change
-
+$2,889,804
-
Number of buys
-
51
-
Number of sells
-
49
-
Price
-
$15.99
Institutional Holders of Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) as of Q2 2025
As of 30 Jun 2025 Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) had 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 24,065,900 shares of stock of the company.
Largest 10 holders included Avoro Capital Advisors LLC, RA CAPITAL MANAGEMENT, L.P., QVT Financial LP, BlackRock, Inc., TCG Crossover Management, LLC, Pfizer Inc, VANGUARD GROUP INC, Blue Owl Capital Holdings LP, Octagon Capital Advisors LP, and QIMING U.S. VENTURES MANAGEMENT, LLC.
This table shows 131 institutional shareholders of the security as of 30 Jun 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.